Conference report: Eplerenone in patients with acute STEMI without heart failure

Source: PharmaLive Area: News PharmaLive has reported on results from the REMINDER trial, which evaluated eplerenone in the early treatment of acute ST-segment elevation myocardial infarction (STEMI). These results were presented at the 62nd Annual Scientific Session of the American College of Cardiology.   The REMINDER study included 1,012 patients with acute STEMI without a history of heart failure (HF) or an ejection fraction of <40% and without signs of HF.  They were randomised to treatment (preferably before myocardial reperfusion) with eplerenone (25-50 mg OD) or placebo in addition to standard therapy, with treatment initiated within the first 24 hours of symptom onset (preferably within first 12h). The composite endpoint was defined as the time to first event of cardiovascular (CV) mortality, re-hospitalisation or extended initial hospital stay due to diagnosis of HF, sustained ventricular tachycardia or fibrillation, EF<40% after 1 month, or an elevation of BNP/ NT-proBNP after 1 ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news